重组溶瘤痘病毒rVV-CCL5-SSTR2-Luc+的构建及其杀瘤活性

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (4): 460-468.

重组溶瘤痘病毒rVV-CCL5-SSTR2-Luc+的构建及其杀瘤活性

李丹洋^1,2, 方敬敬^1,2, 唐慧^1,2*

1.云南省第一人民医院/昆明理工大学附属医院临床基础医学研究所云南省临床病毒学重点实验室昆明市肿瘤分子与免疫防治重点实验室,云南昆明 650032;
2.昆明理工大学医学院,云南昆明 650504

收稿日期:2019-08-03 修回日期:2020-01-07 出版日期:2020-04-05 发布日期:2020-04-06
通讯作者: *htang1122@aliyun.com
基金资助:
国家自然科学基金(81460463);云南省卫生和计划生育委员会医学学科带头人培养基金(D-201642);云南省科技厅科技计划[2019FE001(-173)];云南省临床病毒学重点实验室基金(2018DG010);昆明市肿瘤分子与免疫重点实验室基金(2018-1-A-17334)

Construction of three strains of recombinant oncolytic vaccinia virus and their anti-tumor activity

LI Dan-yang^1,2, FANG Jing-jing^1,2, TANG Hui^1,2*

1. Yunnan Province Key Laboratory of Clinical Virology, Kunming Key Laboratory of Tumor Molecular & Immune Prevention, Institute of Basic and Clinical Medical Sciences, the First people's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032;
2. College of Medicine, Kunming University of Science and Technology, Kunming 650504, China

Received:2019-08-03 Revised:2020-01-07 Online:2020-04-05 Published:2020-04-06
Contact: *htang1122@aliyun.com

摘要/Abstract

摘要： 目的在体外构建携带CCL5和SSTR2双基因的重组溶瘤痘病毒,并初步检测其溶瘤活性。方法利用基因工程策略,分步构建重组痘病毒真核表达质粒pSC65-CCL5-SSTR2-Luc+;经同源重组痘病毒Western Reverse (WR)株和23轮筛选纯化后,获得纯化的重组溶瘤痘病毒rVV-CCL5-SSTR2-Luc+;经扩大培养及浓缩纯化后获得高滴度的重组溶瘤痘病毒,用ELISA和Western blot分别验证感染重组溶瘤痘病毒的HeLa细胞CCL5和SSTR2的表达变化;用CCK-8法检测了rVV-CCL5-SSTR2-Luc+对两株肿瘤细胞系的杀伤活力。结果成功构建了重组痘病毒真核表达质粒pSC65-CCL5-SSTR2-Luc+;经同源重组、筛选纯化和浓缩后,获得滴度为9.4×10⁸ PFU/mL的重组溶瘤痘病毒rVV-CCL5-SSTR2-Luc+;ELISA和Western blot结果表明,HeLa细胞感染rVV-CCL5-SSTR2-Luc+后,其CCL5和SSTR2蛋白表达水平显著高于对照组rVV-Luc+(分别为P＜0.05和P＜0.01);CCK8结果表明,rVV-CCL5-SSTR2-Luc+对人胚肾上皮细胞HEK293T杀伤活力极低,而rVV-CCL5-SSTR2-Luc+对两株肿瘤细胞系的杀伤活力均随感染时间逐渐增强。并且rVV-CCL5-SSTR2-Luc+对肿瘤细胞的杀伤活力较之对照组rVV-Luc+均显著升高(HCT116: 感染48 h时P＜0.05;Hela: 感染48 h时P＜0.05,72 h时P＜0.01)。结论本研究成功构建并获得了纯化的重组痘病毒rVV-CCL5-SSTR2-Luc+,并初步验证了其杀瘤活性,为开展后续体内外实验奠定了实验基础。

关键词: 溶瘤痘病毒, 同源重组, CCL5, SSTR2

Abstract: Objective The aim of this study is to construct a recombinant oncolytic vaccinia virus with CCL5 and SSTR2 genes and to detect its antitumor activity. Methods Recombinant vaccinia virus eukaryotic expression plasmid pSC65-CCL5-SSTR2-Luc+ was constructed. The purified recombinant oncolytic vaccinia virus rVV-CCL5-SSTR2-Luc+ was obtained after homologous recombination with WR vaccinia virus and 23 rounds of screen- ing and purification. The concentrated recombinant oncolytic vaccinia virus was abtained by expanded culture, concentration and purification. The expression changes of CCL5 and SSTR2 in HeLa cells after oncolytic vaccinia virus infection were determined by ELISA and Western blot respectively. The killing activity of rVV-CCL5-SSTR2-Luc+ on two tumor cell lines was detected by CCK-8. Results The recombinant vaccinia eukaryotic expression plasmid pSC65-CCL5-SSTR2-Luc+ was constructed successfully; Purified recombinant oncolytic vaccinia virus rVV-CCL5-SSTR2-Luc+ with titer as 9.4×10⁸ PFU/mL was obtained after homologous recombination, screening, purification and concentration; ELISA and Western blot results showed that after HeLa cells were infected with rVV-CCL5-SSTR2-Luc+, the expression level of CCL5 and SSTR2 protein in HeLa cells was significantly higher than those in the control group rVV-Luc+ (P＜0.05 and P＜0.01, respectively); The results of CCK8 indicated that the killing activity of rVV-CCL5-SSTR2-Luc+ on human embryonic renal epithelial cells HEK293T was very low, while the killing activity of rVV-CCL5-SSTR2-Luc+ on two tumor cell lines increased gradually with the infection time. In addition, the killing activity of oncolytic vaccinia virus rVV-CCL5-SSTR2-Luc+ on tumor cells was significantly increased as compared with that of the control group rVV-Luc+ (HCT116: 48 h after infection P＜0.05; Hela: at 48 h, P＜0.05; at 72 h, P＜0.01). Conclusions Purified recombinant oncolytic vaccinia virus rVV-CCL5-SSTR2-Luc+ is constructed and purified successfully, its tumoricidal activity is verified preliminarily, so this conclusion lays out an experimental foundation for subsequent in vivo and in vitro researches.

Key words: oncolytic vaccinia virus, homologous recombination, CCL5, SSTR2

中图分类号:

李丹洋, 方敬敬, 唐慧. 重组溶瘤痘病毒rVV-CCL5-SSTR2-Luc+的构建及其杀瘤活性[J]. 基础医学与临床, 2020, 40(4): 460-468.

LI Dan-yang, FANG Jing-jing, TANG Hui. Construction of three strains of recombinant oncolytic vaccinia virus and their anti-tumor activity[J]. Basic & Clinical Medicine, 2020, 40(4): 460-468.

参考文献

[1]李丹洋, 唐慧. 基因改造的溶瘤痘病毒在肿瘤治疗中的研究进展[J]. 中国细胞生物学学报, 2016, 8: 1523-1534.
[2]Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics[J]. J Immunother Cancer, 2019, 7: 6.
[3]Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque forma-tion in mice[J]. Circ Res, 2004, 94: 253-261.
[4]Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors[J]. Endocr Rev, 1991, 12: 450-482.
[5]Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology[J]. J Clin Oncol, 2015, 33: 786-809.
[6]Dizon DS, Krilov L, Cohen E, et al. Clinical cancer advances 2016: annual report on progress against cancer from the American society of clinical oncology[J]. J Clin Oncol, 2016, 34: 987-1011.
[7]Burstein HJ, Krilov L, Aragon-Ching JB, et al. Clinical cancer advances 2017: annual report on progress against cancer from the American society of clinical oncology[J]. J Clin Oncol, 2017, 35: 1341-1367.
[8]Heymach J, Krilov L, Alberg A, et al. Clinical cancer advances 2018: annual report on progress against cancer from the American society of clinical oncology[J]. J Clin Oncol, 2018, 36: 1020-1044.
[9]Pal SK, Miller MJ, Agarwal N, et al. Clinical cancer advances 2019: annual report on progress against cancer from the American society of clinical oncology[J]. J Clin Oncol, 2019, 37: 834-849.
[10]Chan WM, McFadden G. Oncolytic poxviruses[J]. Annu Rev Virol, 2014, 1: 119-141.
[11]Mejías-Pérez E, Carreño-Fuentes L, Esteban M. Development of a safe and effective vaccinia virus oncolytic vector WR-Δ4 with a set of gene deletions on several viral pathways[J]. Mol Ther Oncolytics, 2018, 8: 27-40.
[12]Poh A. First oncolytic viral therapy for melanoma[J]. Cancer Discov, 2016, 6: 6.
[13]Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced mela-noma[J]. Immunotherapy, 2015, 7: 611-619.